Who are H077 sustained-release tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROAMPHETAMINE, Escitalopram, venlafaxine, lithium, SSRI/SNRI, Serdexmethylphenidate/dexmethylphenidate, Methamphetamine Hydrochloride Tablets, Methylphenidate extended-release; Atomoxetine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/h077-sustained-release-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

H077 sustained-release tablet — Competitive Intelligence Brief

H077 sustained-release tablet (H077 sustained-release tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: norepinephrine reuptake inhibitor. Area: Depression.

phase 3 norepinephrine reuptake inhibitor norepinephrine transporter Depression Small molecule Live · refreshed every 30 min

Target snapshot

H077 sustained-release tablet (H077 sustained-release tablet) — Shanghai Huilun Pharmaceutical Co., Ltd.. H077 sustained-release tablet is a medication that works by inhibiting the reuptake of a specific neurotransmitter.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
H077 sustained-release tablet TARGET	H077 sustained-release tablet	Shanghai Huilun Pharmaceutical Co., Ltd.	phase 3	norepinephrine reuptake inhibitor	norepinephrine transporter
DEXTROAMPHETAMINE	DEXTROAMPHETAMINE		marketed	Central nervous system stimulant	Dopamine transporter (DAT), Norepinephrine transporter (NET)	1955-01-01
Escitalopram, venlafaxine, lithium	Escitalopram, venlafaxine, lithium	K. Lieb	marketed	Antidepressant combination (SSRI + SNRI + mood stabilizer)	Serotonin transporter (SERT), norepinephrine transporter (NET), and lithium-responsive intracellular signaling pathways
SSRI/SNRI	SSRI/SNRI	UCB Pharma	marketed	SSRI/SNRI	Serotonin transporter (SERT); norepinephrine transporter (NET) for SNRIs
Serdexmethylphenidate/dexmethylphenidate	Serdexmethylphenidate/dexmethylphenidate	NYU Langone Health	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Methamphetamine Hydrochloride Tablets	Methamphetamine Hydrochloride Tablets	Oregon Health and Science University	marketed	Sympathomimetic amine; central nervous system stimulant	Dopamine transporter (DAT); norepinephrine transporter (NET); trace amine-associated receptor 1 (TAAR1)
Methylphenidate extended-release; Atomoxetine	Methylphenidate extended-release; Atomoxetine	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	marketed	Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine)	Dopamine transporter and norepinephrine transporter (methylphenidate); norepinephrine transporter (atomoxetine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-24 — DEXTROAMPHETAMINE · 9456993 · Formulation · US
2033-10-24 — DEXTROAMPHETAMINE · 9474722 · Formulation · US
2042-01-06 — DEXTROAMPHETAMINE · 11559501 · Formulation · US

Sponsor landscape (norepinephrine reuptake inhibitor class)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Kwang-Ha Yoo · 1 drug in this class
Sanofi · 1 drug in this class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). H077 sustained-release tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/h077-sustained-release-tablet. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab